A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 30 Sep 2024
At a glance
- Drugs VTX 002 (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Oppilan Pharma
- 08 Aug 2024 According to a Ventyx Biosciences media release, the company recently completed the long-term extension (LTE) portion of the Phase 2 trial.
- 09 May 2024 According to a Ventyx Biosciences media release, the company recently completed a productive End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and we expect to conduct a Scientific Advice meeting with the European Medicines Agency (EMA) during the second quarter of this year.
- 27 Feb 2024 According to a Ventyx Biosciences media release, the company will provide data from the open-label extension part of this study at virtual investor event on March 11th.